MannKind Investor Relations Material
Latest events
Q1 2025
MannKind
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MannKind Corporation
Access all reports
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.
Key slides for MannKind Corporation
Q2 2024
MannKind Corporation
Q2 2024
MannKind Corporation
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
MNKD
Country
🇺🇸 United States